STARBOARD Triplet Hits 33-Month PFS in BRAF-Mutant Melanoma

Median progression-free survival of 33.0 months versus 3.4 months. That is the headline result from the phase 3 STARBOARD trial, and it is the number Dirk Schadendorf, MD, believes should redraw first-line decision-making in unresectable locally advanced or metastatic BRAF V600-mutant melanoma.

The confirmed objective response rate told the same story: 70.0% with the triplet of encorafenib (Braftovi), binimetinib (Mektovi) and pembrolizumab (Keytruda), against 32.7% with placebo plus pembrolizumab. The regimen cut the risk of disease progression or death by 67% (HR, 0.33). Overall survival data remain immature, but the trend favors the triplet (HR, 0.71).

How STARBOARD was built

STARBOARD is a randomized, double-blind study testing first-line encorafenib, a BRAF inhibitor, plus binimetinib, a MEK inhibitor, plus pembrolizumab, an anti-PD-1 checkpoint inhibitor, against placebo plus pembrolizumab. It enrolled 220 patients with BRAF V600E/K-mutant cutaneous melanoma who had received no prior first-line systemic therapy.

Patients were randomized 1:1. The primary endpoint was objective response rate by blinded independent central review, with progression-free survival as a key secondary endpoint. Both endpoints were met.

What about toxicity?

The efficacy gap comes with a toxicity gap. Grade 3/4 treatment-emergent adverse events occurred in 70% of patients on the triplet versus 39% in the control arm. Investigators reported no new safety signals and no grade 5 treatment-related adverse events.

What does this change for the clinician?

Schadendorf frames the practical shift plainly. There is already a defined group of patients for whom targeted therapy is typically considered, and every one of them should now be evaluated as a candidate for the triplet regimen. Not the doublet. The triplet.

The bigger question, he says, is whether BRAF/MEK inhibition alone, without checkpoint blockade, remains a reasonable approach at all. He calls this the great question in the field. The reason is durability: the PFS seen with the triplet has not been matched by the median PFS reported in any BRAF/MEK clinical trial to date.

Who is the clearest fit?

Schadendorf identifies two groups he views as prime candidates for the triplet:

• Patients with symptomatic disease
• Patients with fast tumor kinetics

In both situations, clinicians would usually reach for nivolumab (Opdivo) plus ipilimumab (Yervoy). For patients with BRAF V600-mutant melanoma, he now describes the triplet as a strong alternative to that combination.

The decision point he addresses is the classic one in this disease: targeted therapy versus checkpoint blockade. STARBOARD blurs that line by merging the two strategies into a single first-line regimen, and the magnitude of the PFS difference, roughly a tenfold gap in medians, makes the case hard to ignore. Whether OS matures into a statistically significant advantage, and how the 70% grade 3/4 rate plays out in broader practice, will shape how quickly the triplet becomes the default rather than the alternative.